• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • WORLD EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • WORLD EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks

    Cellular Biomedicine Group Obtained NCI Patent License

    Gabrielle Lakusta
    Oct. 03, 2018 09:09AM PST
    Pharmaceutical Investing

    Cellular Biomedicine Group (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced it has entered into a Patent License Agreement with the National Cancer Institute (“NCI”), an institute of the National Institutes of Health, within the Department of Health and Human Services. As …

    Cellular Biomedicine Group (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced it has entered into a Patent License Agreement with the National Cancer Institute (“NCI”), an institute of the National Institutes of Health, within the Department of Health and Human Services.

    As quoted in the press release:

    Pursuant to the License Agreement, NCI granted CBMG a non-exclusive, sub-licensable worldwide license to develop, manufacture and commercialize next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology to treat a variety of cancers.

    “We are extremely pleased to finalize this License Agreement as this next generation TIL technology will fortify our clinical development pipelines for solid tumors.  It is a significant extension of our CAR/TCR-T pipelines against solid tumors in the immuno-oncology platform,” stated Tony (Bizuo) Liu, Chief Executive Officer of CBMG. “The medical oncology community is very aware of the innovative work using T cell-based immunotherapy and autologous TIL transfer for the treatment of various cancers. We look forward to continuing to advance this field.”

    Click here to read the full press release.

    stem cell therapiescellular biomedicine group
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×